佐力药业：接受中信证券等投资者调研

Group 1 - The core viewpoint of the article is that Zhaoli Pharmaceutical (SZ 300181) has engaged with investors through a research meeting, providing insights into its business operations and revenue composition [1] - As of the report, Zhaoli Pharmaceutical's market capitalization stands at 12.3 billion yuan [1] - The revenue composition for Zhaoli Pharmaceutical from January to June 2025 is as follows: pharmaceutical manufacturing accounts for 78.39%, pharmaceutical distribution for 21.35%, and other businesses for 0.26% [1] Group 2 - The company’s general manager, Wang Tao, participated in the investor meeting, addressing questions from attendees [1] - The company is actively engaging with investors to enhance transparency and provide updates on its operational performance [1]